Hepatocellular Carcinoma
Heavy alcohol use, gene variant heighten risk for HCC, mortality in HBV-related cirrhosis
Patients with cirrhosis who have hepatitis B virus infection and a history of heavy alcohol use are at higher risk for hepatocellular carcinoma and mortality, according to a study published in JAMA Network Open.
HCC surveillance underused in most patients with cirrhosis; screening improvements needed
Hepatocellular carcinoma surveillance was underutilized in more than 80% of patients with cirrhosis, with lack of clinician orders and lack of patient adherence cited as common screening barriers, according to a study in JAMA Network Open.
Phase 3 studies of pembrolizumab fail to meet key survival endpoints
AI-based Cancer Detection and the Future of Care
In this episode, host Shikha Jain, MD, speaks with Helio Genomics’ Justin Chen Li about the ways in which AI has been incorporated into oncologic care, how this technology can improve care disparities, and more.
TACE plus microwave ablation shows comparable survival, ‘better tumor control’ for HCC
Transcatheter arterial chemoembolization alone and with microwave ablation yielded comparable overall survival rates in patients with recurrent small hepatocellular carcinoma after resection, per research in BMC Gastroenterology.
Black, Hispanic patients with hepatocellular carcinoma less likely to receive immunotherapy
Black and Hispanic patients with advanced hepatocellular carcinoma had a lower likelihood than their white counterparts of receiving immunotherapy, which appeared more effective than chemotherapy for the disease, according to study results.
No difference in HCC risk between tenofovir, entecavir for chronic HBV infection
There was no clinically meaningful difference in the risk for hepatocellular carcinoma between patients taking tenofovir vs. entecavir to treat chronic hepatitis B virus infection, according to study results published in JAMA Network Open.
Alcohol use disorders may drive HCC progression in patients with diabetes
LONDON — Alcohol misuse was a primary trigger for progression of liver disease to hepatocellular carcinoma among a subset of French patients with type 2 diabetes, according to data presented at the International Liver Congress.
FDA grants orphan drug designation to rencofilstat for hepatocellular carcinoma
The FDA granted orphan drug designation to rencofilstat for treatment of hepatocellular carcinoma, according to the agent’s manufacturer.
Post-treatment liver stiffness predicts complications, HCC in hepatitis C
SAN DIEGO — Liver stiffness assessment predicted liver-related complications and hepatocellular carcinoma development among patients with hepatitis C following direct-acting antiviral treatment, according to research.